Family · gh
Sermorelin
GRF 1-29; GHRH(1-29)-NH2; Geref (discontinued brand); sermorelin acetate
Sermorelin is a synthetic 29-amino-acid fragment of human growth hormone-releasing hormone (GHRH 1-29), which retains the full biological activity of the native 44-amino-acid hormone. It binds the GHRH receptor on pituitary somatotroph cells, stimulating physiologic, pulsatile release of endogenous growth hormone, which secondarily raises IGF-1. Because it works upstream of the pituitary rather than supplying GH directly, its effect depends on a somatotroph population still capable of responding, and it preserves the body's own feedback control (somatostatin, negative feedback from IGF-1) in a way that direct GH administration does not.
Sermorelin has a real, if dated, evidence base: it was studied through the 1980s-90s as both a diagnostic agent for GH deficiency and a treatment, and was FDA-approved (as Geref) for diagnostic use in 1990 and for pediatric growth hormone deficiency in 1997. A controlled study in healthy older men (Corpas et al., 1992) showed twice-daily GRF(1-29) administration reversed age-related declines in pulsatile GH secretion and normalized IGF-1 levels over several weeks. Pediatric trials supporting the Geref approval showed it increased growth velocity in children with idiopathic GH deficiency, though generally less consistently and less potently than direct recombinant GH therapy, which is why it was a second-line option even at approval. Long-term outcome data (adult height, body composition, mortality) and modern trials in adults using today's compounded formulations are lacking.
- Historically: diagnostic testing of pituitary GH reserve, and treatment of pediatric growth hormone deficiency (the approved indications before discontinuation)
- Research interest in GHRH-receptor stimulation of the GH/IGF-1 axis, including in older adults with reduced GH pulsatility
Educational overview only — no dosing instructions in the public hub.
Reported effects from clinical use include injection-site reactions (pain, redness, induration), flushing, headache, and transient dizziness or somnolence; because it stimulates the GH/IGF-1 axis it carries the same class caution as other GH secretagogues regarding active or suspected malignancy, and its use requires an intact hypothalamic-pituitary axis to be effective at all. Compounded sermorelin available today is not subject to the same batch-release, potency, and impurity testing that the original approved Geref product underwent, so potency and consistency can vary by pharmacy or supplier.
Because the original FDA-approved product is discontinued, essentially all sermorelin in circulation today is either licensed compounded product (US, via a prescriber and 503A/503B pharmacy) or unregulated research-chemical material. For any non-pharmacy source, an independent third-party CoA — identity and purity by HPLC, quantification, and mass-spectrometry confirmation — is the minimum bar, and lot numbers should be checked against the vial/product in hand.
US: sermorelin acetate was FDA-approved (Geref, and a diagnostic formulation) but the manufacturer discontinued both NDAs for commercial reasons in 2008-2009; sermorelin remains listed on FDA's 503A bulks list, so licensed compounding pharmacies can still legally prepare it with a valid prescription, which is how it is mainly used clinically in the US today. EU/UK: no current marketing authorization; it is not an approved medicine in the EU or UK and any product obtained outside a licensed pharmacy/prescriber pathway should be treated as an unapproved/RUO substance.
Frequently asked questions
- What is Sermorelin used for?
- Historically: diagnostic testing of pituitary GH reserve, and treatment of pediatric growth hormone deficiency (the approved indications before discontinuation). Research interest in GHRH-receptor stimulation of the GH/IGF-1 axis, including in older adults with reduced GH pulsatility. Sermorelin has a real, if dated, evidence base: it was studied through the 1980s-90s as both a diagnostic agent for GH deficiency and a treatment, and was FDA-approved (as Geref) for diagnostic use in 1990 and for pediatric growth hormone deficiency in 1997. A controlled study in healthy older men (Corpas et al., 1992) showed twice-daily GRF(1-29) administration reversed age-related declines in pulsatile GH secretion and normalized IGF-1 levels over several weeks. Pediatric trials supporting the Geref approval showed it increased growth velocity in children with idiopathic GH deficiency, though generally less consistently and less potently than direct recombinant GH therapy, which is why it was a second-line option even at approval. Long-term outcome data (adult height, body composition, mortality) and modern trials in adults using today's compounded formulations are lacking.
- Is Sermorelin legal in Europe?
- US: sermorelin acetate was FDA-approved (Geref, and a diagnostic formulation) but the manufacturer discontinued both NDAs for commercial reasons in 2008-2009; sermorelin remains listed on FDA's 503A bulks list, so licensed compounding pharmacies can still legally prepare it with a valid prescription, which is how it is mainly used clinically in the US today. EU/UK: no current marketing authorization; it is not an approved medicine in the EU or UK and any product obtained outside a licensed pharmacy/prescriber pathway should be treated as an unapproved/RUO substance.
- What are the risks and side effects of Sermorelin?
- Reported effects from clinical use include injection-site reactions (pain, redness, induration), flushing, headache, and transient dizziness or somnolence; because it stimulates the GH/IGF-1 axis it carries the same class caution as other GH secretagogues regarding active or suspected malignancy, and its use requires an intact hypothalamic-pituitary axis to be effective at all. Compounded sermorelin available today is not subject to the same batch-release, potency, and impurity testing that the original approved Geref product underwent, so potency and consistency can vary by pharmacy or supplier.
- How is the quality of Sermorelin assessed?
- Because the original FDA-approved product is discontinued, essentially all sermorelin in circulation today is either licensed compounded product (US, via a prescriber and 503A/503B pharmacy) or unregulated research-chemical material. For any non-pharmacy source, an independent third-party CoA — identity and purity by HPLC, quantification, and mass-spectrometry confirmation — is the minimum bar, and lot numbers should be checked against the vial/product in hand.